Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
1992-4-9
|
| pubmed:abstractText |
The authors have developed an enzyme immunoassay test system for measurements of the specific cerebral alpha 2-glycoprotein (alpha 2-GP), whose sensitivity limit is 0.8 ng/ml. Blood serum alpha 2-GP level is 7 ng/ml, cerebrospinal fluid level is 12.8 ng/ml in health; detection of alpha 2-GP in these biological fluids in concentrations surpassing such values indicates impairment of the hematoencephalic barrier permeability and active release of the cerebral proteins into the blood. The hematoencephalic barrier is most frequently disrupted in the brain-blood direction in purulent meningitis, encephalitis, open craniocerebral injuries; such impairments may be detected with the use of alpha 2-GP measurements. A direct correlation between the blood serum alpha 2-GP level and the severity of the disease clinical course has been revealed.
|
| pubmed:language |
rus
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0023-6748
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
37-42
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading | |
| pubmed:year |
1991
|
| pubmed:articleTitle |
[The immunoenzyme analysis of the specific alpha2-glycoprotein in the brain in patients with neuropsychic diseases].
|
| pubmed:publicationType |
Journal Article,
English Abstract
|